Startseite › Prostatakrebs › Pennsylvania › Philadelphia
Klinische Studien zu Prostatakrebs in Philadelphia, PA
44 Studien zu Prostatakrebs suchen Teilnehmer an Standorten in und um Philadelphia (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Teilnehmer gesuchtPhase 1/2
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Teilnehmer gesuchtPhase 3
- Thomas Jefferson University Hospital, Philadelphia
- Jefferson Torresdale Hospital, Philadelphia
- Asplundh Cancer Pavilion, Willow Grove · 13 mi entfernt
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Teilnehmer gesuchtBeobachtungsstudieGesunde Freiwillige willkommen
- Reading Hospital McGlinn Cancer Institute at Phoenixville, Phoenixville · 22 mi entfernt
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Teilnehmer gesuchtPhase 1
- Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia
DESTINY-PANTUMOUR04
Teilnehmer gesuchtBeobachtungsstudie
- Research Site, Philadelphia
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Teilnehmer gesuchtPhase 3
- Fox Chase Cancer Center ( Site 0076), Philadelphia
- MidLantic urology ( Site 0022), Bala-Cynwyd · 5 mi entfernt
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Teilnehmer gesuchtPhase 3
- MidLantic urology, Bala-Cynwyd · 5 mi entfernt
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Teilnehmer gesuchtPhase 2/3
- Fox Chase Cancer Center, Philadelphia
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Teilnehmer gesuchtPhase 2
- Philadelphia MultiService Center, Philadelphia, PA, Philadelphia
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Teilnehmer gesuchtPhase 3
- Perelman Center for Advanced Medicine ( Site 0067), Philadelphia
- Abramson Cancer Center - Penn Medicine ( Site 0079), Philadelphia
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
Teilnehmer gesuchtPhase 1/2
- GSK Investigational Site, Philadelphia
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
Teilnehmer gesuchtPhase 1
- Thomas Jefferson University, Philadelphia
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
Teilnehmer gesucht
- MidLantic Urology, Bala-Cynwyd · 5 mi entfernt
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Teilnehmer gesuchtPhase 3
- Christiana Care Health System-Concord Health Center, Chadds Ford · 23 mi entfernt
- Christiana Care Health System-Wilmington Hospital, Wilmington · 25 mi entfernt
A Study of Tarlatamab for People With Prostate Cancer
Teilnehmer gesuchtPhase 2
- Thomas Jefferson University Hospital, Philadelphia
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Teilnehmer gesuchtPhase 1
- Thomas Jefferson University, Philadelphia
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
Teilnehmer gesuchtPhase 2
- Abramson Cancer Center of the University of Pennsylvania, Hospital of the University of Pennsylvania, Philadelphia
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Teilnehmer gesuchtPhase 3
- Penn Presbyterian Medical Center, Philadelphia
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Teilnehmer gesuchtPhase 1/2
- University of Pennsylvania, Perelman School of Medicine, Philadelphia
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Teilnehmer gesuchtPhase 1
- Thomas Jefferson University Honickman Center, Philadelphia
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
Teilnehmer gesuchtPhase 1
- Thomas Jefferson University, Philadelphia
PSMA PET Combined With MRI for the Detection of PCa
Teilnehmer gesuchtPhase 3Gesunde Freiwillige willkommen
- MidLantic Urology, Philadelphia
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Teilnehmer gesuchtPhase 1
- Investigative Site #109, Philadelphia
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Teilnehmer gesuchtPhase 3
- Philadelphia Veterans Administration Medical Center, Philadelphia
- Christiana Care Health System-Concord Health Center, Chadds Ford · 23 mi entfernt
- Christiana Care Health System-Wilmington Hospital, Wilmington · 25 mi entfernt
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Teilnehmer gesuchtPhase 1
- MidLantic Urology, Bala-Cynwyd · 5 mi entfernt
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Teilnehmer gesuchtPhase 1
- Thomas Jefferson University, Philadelphia
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Teilnehmer gesuchtPhase 1/2
- Thomas Jefferson University Hospital, Philadelphia
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
Teilnehmer gesuchtPhase 2
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia
TERPS Trial for de Novo Oligometastic Prostate Cancer
Teilnehmer gesuchtPhase 2
- Sidney Kimmel Cancer Center at Jefferson Health, Philadelphia
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Teilnehmer gesuchtBeobachtungsstudie
- Fox Chase Cancer Center - Temple Health, Philadelphia
Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
Teilnehmer gesuchtBeobachtungsstudieGesunde Freiwillige willkommen
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network
Teilnehmer gesuchtBeobachtungsstudieGesunde Freiwillige willkommen
- Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia
Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation
Teilnehmer gesucht
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Philadelphia
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
Teilnehmer gesuchtPhase 2/3
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Teilnehmer gesuchtPhase 1/2
- Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center, Philadelphia
Study of AZD0754 in Participants With Metastatic Prostate Cancer
Teilnehmer gesuchtPhase 1/2
- Research Site, Philadelphia
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Teilnehmer gesuchtPhase 1
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
- Fox Chase Cancer Center, Philadelphia
Hypofractionated WPPT With HDR Boost
Teilnehmer gesuchtPhase 2
- University of Pennsylvania, Philadelphia
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Teilnehmer gesuchtPhase 1
- MidLantic Urology, Bala-Cynwyd · 5 mi entfernt
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Teilnehmer gesuchtPhase 4
- Albert Einstein Healthcare Network, Philadelphia
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
Teilnehmer gesuchtPhase 3
- Christiana Care Health System-Concord Health Center, Chadds Ford · 23 mi entfernt
- Christiana Care Health System-Wilmington Hospital, Wilmington · 25 mi entfernt
Prostate Tissue BioBank
Teilnehmer gesuchtBeobachtungsstudie
- University of Pennsylvania, Philadelphia
Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer
Teilnehmer gesucht
- Fox Chase Cancer Center, Philadelphia
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Teilnehmer gesuchtBeobachtungsstudie
- Massive Bio SYNERGY-AI site, Philadelphia
Prostatakrebs-Studien in anderen Städten
- New York City, NY103 Studien
- Houston, TX76 Studien
- Los Angeles, CA61 Studien
- Boston, MA59 Studien
- St. Louis, MO46 Studien
- Chicago, IL45 Studien
- San Francisco, CA45 Studien
- Baltimore, MD43 Studien
- Nashville, TN43 Studien
- Seattle, WA42 Studien
- Washington, DC38 Studien
- Dallas, TX36 Studien
Weitere Studien in Philadelphia
- Krebs (alle Arten)59 Studien
- Brustkrebs56 Studien
- Nichtkleinzelliges Lungenkarzinom51 Studien
- Metastasierender Krebs46 Studien
- Kolorektales Karzinom44 Studien
- Eierstockkrebs44 Studien
- Lungenkrebs36 Studien
- Akute myeloische Leukämie34 Studien
- Herzinsuffizienz31 Studien
- Endometriumkarzinom28 Studien
- Depression26 Studien
- Bauchspeicheldrüsenkrebs26 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 06.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.